Skip to content

Septerna, Inc. SEPN Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$47.16M

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: Septerna, Inc.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s net proceeds from sales of subsidiary shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s net proceeds from sales of subsidiary shares?
Septerna, Inc. (SEPN) reported net proceeds from sales of subsidiary shares of $0 in Q4 2025.
How has Septerna, Inc.'s net proceeds from sales of subsidiary shares changed year-over-year?
Septerna, Inc.'s net proceeds from sales of subsidiary shares decreased by 100.0% year-over-year, from $75.7M to $0.
What does net proceeds from sales of subsidiary shares mean?
This represents the gross or net cash proceeds generated from the company's initial public offering of equity securities. It signifies a major capital infusion intended to fund long-term research, clinical trials, and platform development. Investors use this to evaluate the company's capitalization status and its ability to sustain operations through public market funding.